FY05 Primary Objectives
Focus our efforts to properly contextualize the AiMI results and emphasize the unique clinical benefits of AngioJet
Closely manage our expenses as we navigate the somewhat uncharted waters and try to forecast the impact of the AiMI results
Continue our priorities towards significantly advancing our overall AngioJet System technology
Increase our focus on venous thromboembolism, a large and undeveloped market including DVT and PE